Talquetamab,Teclistamab,Daratumumab
Janssen,genmab
['talquetamab']
these are main results of the first-ever reported dual bispecific combination in haematological malignancies, talquetamab+talquetamab. do you want to know more about this trial? right after this session we will share an interview with dr mateos summarising these results #eha2023 
A network of highly efficient, effective and sustainable myeloma and AL amyloidosis patient organisations across Europe